Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2018

  • ID: 4592000
  • Report
  • 99 pages
  • GlobalData
1 of 3
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2018

Summary

The "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from the author’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2. Sector Highlights

3. Mergers and Acquisitions - Americas

4. Mergers and Acquisitions - Europe, Middle East, and Africa

5. Mergers and Acquisitions - Asia-Pacific

6. Appendix
6.1. Abbreviations
6.2. Methodology
6.3. Coverage
6.4. Secondary Research
6.5. Contact
6.6. Disclaimer

List of Tables
Table 1: Upstream Oil and Gas Transaction Multiples December 2017-May 2018
Table 2: Top Upstream Oil and Gas Transactions in May 2018
Table 3: Upstream Oil and Gas Americas Transaction Multiples December 2017-May 2018
Table 4: Upstream Oil and Gas Americas Rumored M&A December 2017-May 2018
Table 5: Top Upstream Oil and Gas Transactions in May 2018
Table 6: Upstream Oil and Gas EMEA Transaction Multiples December 2017-May 2018
Table 7: Upstream Oil and Gas EMEA Rumored M&A December 2017-May 2018
Table 8: Top Upstream Oil and Gas Transactions in May 2018
Table 9: Upstream Oil and Gas APAC Transaction Multiples December 2017-May 2018
Table 10: Upstream Oil and Gas APAC Rumored M&A December 2017-May 2018

List of Figures
Figure 1: Upstream M&A Deal Value and Count
Figure 2: Upstream Oil and Gas Regional Deal Share and Value YTD 2018
Figure 3: Upstream Oil and Gas Deal Share and Value by Terrain YTD 2018
Figure 4: Upstream Oil and Gas Americas Deal Value and Count
Figure 5: Upstream Oil and Gas Americas Top 10 Buyers December 2017-May 2018
Figure 6: Upstream Oil and Gas Americas Top 10 Sellers December 2017-May 2018
Figure 7: Upstream Oil and Gas EMEA Deal Value and Count
Figure 8: Upstream Oil and Gas EMEA Top 10 Buyers December 2017-May 2018
Figure 9: Upstream Oil and Gas EMEA Top 10 Sellers December 2017-May 2018
Figure 10: Upstream Oil and Gas APAC Deal Value and Count
Figure 11: Upstream Oil and Gas APAC Top 10 Buyers December 2017-May 2018
Figure 12: Upstream Oil and Gas APAC Top 10 Sellers December 2017-May 2018
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll